Pentraxin-3 and Presepsin ki sepsis ke nidaan me upyogita

Not yet recruiting

Conditions: Bacterial infection, unspecified,

Registration Number: CTRI/2021/09/036689

Lead Sponsor: AIIMS JODHPUR

Brief Summary: Sepsis is a clinical syndrome triggered by infection.

While procalcitonin is used most common sepsis biomarker, its reliability is still an issue.

Hence, we are planning to explore the utility of 2 new sepsis biomarkers, pentraxin-3 and presepsin.

In this study, we will collect samples of these biomarkers on day 1, 3, 7, and at the time of discharge or death.

We will correlate these biomarkers and their utility in the prognosis of patients with sepsis in ICU.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

Adult patients having clinical features suggestive of sepsis.

Exclusion Criteria

Exclusion criteria are age < 18 years, patients with terminal stage of disease (malignant cancer of any type, acquired immunodeficiency syndrome, end-stage liver or renal disease) patient who have received antibiotics and patient/relatives who will not consent to inclusion.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To study Changes in Pentraxin-3 and Presepsin levels in patients with sepsis during first week of ICU admission	Day 1 \| 3 \| 7 \| death or discharge

Secondary Outcome Measures

Name	Time	Method
1.To study the utility of Pentraxin-3 and Presepsin with prognosis of sepsis using sequential organ failure assessment (SOFA) score	2.To study the sensitivity and specificity of Pentraxin-3 and Presepsin for 28 day mortality in critically ill patients

Trial Locations

Locations (1): AIIMS JODHPUR
🇮🇳
Jodhpur, RAJASTHAN, India
AIIMS JODHPUR
🇮🇳Jodhpur, RAJASTHAN, India
DR ANKUR SHARMA
Principal investigator
919654045653
ankuranaesthesia@gmail.com